Migraine Headaches
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention Amgen
Purpose of the Study
• To find out if AMG 334 is safe and effective in migraine prevention
Participants must meet the following criteria
• Male or female between 18 and 65 years of age.
• History of migraine for at least 12 months prior to screening
• 4 to 14 migraine days per month
• Less than 15 headache days per month
Study Design
• Study will take place over approximately 55 weeks
• For the first 12 weeks of the study, you will receive either placebo or AMG 334. After 12 weeks of receiving AMG 334 or placebo, all participants will receive AMG 334 for the next 28 weeks.
Compensation
• You will be compensated $50.00 per visit completed.